Expired activity
Please go to the PowerPak homepage and select a course.

"The Fourth Cornerstone:"
The Expanding Role of Immunotherapy in Oncology

Provided by The University of Tennessee College of Pharmacy, in cooperation with ASiM.
Supported by educational grants from Bristol-Myers Squibb Company.


Immunotherapy has revolutionized treatment and survival outcomes for patients with cancer. Due to their unique mechanisms of action (MOAs), response patterns, and safety profiles, these therapies differ greatly from cytotoxic agents and targeted therapies. Furthermore, the survival benefits of new and emerging immunotherapies are accompanied by high drug costs, making formulary decisions complex. As drug therapy and medical experts, specialty pharmacists play an integral role in cancer therapy and promoting cost-effective therapy utilization, and must be continually updated on these highly unique therapies. Through previously recorded interactive case-based presentations and expert discussion, this archived webcast will present the most up-to-date information on the use of immunotherapies in oncology, their unique MOAs, response patterns, and AE management strategies. This activity will also address issues and challenges in incorporating these therapies into clinical practice to positively impact patient outcomes.


The goal of this activity is to enhance managed care and specialty pharmacists' understanding of the evolving science, response assessment, adverse event management, and pharmacoeconomics regarding immunotherapies in oncology.


This educational initiative is intended for managed care and specialty pharmacists, as well as other pharmacists who are interested in immunotherapies in oncology. No prerequisites required.


The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:

  • DIFFERENTIATE the mechanism of action of immunotherapies from targeted therapies and chemotherapy.
  • IDENTIFY currently approved and investigational immune checkpoint inhibitors and their clinical indications.
  • RECOGNIZE unique disease response patterns and adverse events associated with immunotherapy treatment.
  • DEVELOP strategies to educate patients and other HCPs on the efficacious and safe use of immunotherapy.


acpeThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based program will provide a statement for 1.5 contact hours of credit (0.15 CEUs) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: 1) completing the preassessment; 2) watching, listening to, and participating in the educational activity; and, 3) completing the self-assessment instrument with a score of at least 70%. UAN: 0064-0000-17-207-H01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days. It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/. To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE Monitor.

Type of Activity: Knowledge

Published: September 26, 2017
Expires: September 26, 2018

Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 90 minutes


Participants must complete the activity as described above in the Credit Designation Statement. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of CE credit will be made available immediately. Click on View Certificate and print the CE statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test.


As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Steering Committee reported the following:


Val R. Adams, PharmD, FCCP, BCOP
Associate Professor
Pharmacy Practice and Science Department
College of Pharmacy
University of Kentucky
Lexington, Kentucky
Dr Adams reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Matt Farber, MA
Senior Director
Oncology Disease State
Walgreens Specialty Pharmacy
Deerfield, Illinois
Mr Farber reports holding stock in Walgreens Boot Alliance.


In accordance with ACPE Criteria for Quality, the audience is advised that discussions in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices, including, but not limited to, the following:

  • Carboplatin
  • Cisplatin


The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.


A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at gfarr@utasip.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.


The following is an enduring archived webcast activity that's designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited preassessment, an archived webcast consisting of synced slides and audio, and a CPE postassessment, and evaluation. All 3 sections must be completed to receive CPE credit. A statement of credit will be available online immediately following successful completion of the activity.


Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5


  • Activity Overview and Goals
  • Introduction
  • Role of the Immune System and Immunotherapy in Cancer
  • Approved and Investigational Immune Checkpoint Inhibitors
  • Immune-Related Response Criteria and Adverse Events
  • Pharmacist Role
  • Conclusions and Question and Answer Session

What you are about to view is a previously recorded live webcast. Please note that only "home study" credit will be awarded for participating in this archived presentation. No "live" credits are available.